Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SELB | Series A Convertible Preferred Stock | Award | $10M | +24.8K | $403.47* | 24.8K | Nov 15, 2023 | See Footnote | F1 | |
transaction | SELB | Series A Convertible Preferred Stock | Award | $50M | +124K | $403.47* | 124K | Nov 15, 2023 | Direct | ||
holding | SELB | Common Stock | 86.4K | Nov 13, 2023 | By wife | ||||||
holding | SELB | Common Stock | 7.29M | Nov 13, 2023 | Direct | ||||||
holding | SELB | Common Stock | 29.9M | Nov 13, 2023 | See Footnote | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -6.41K | -100% | 0 | Nov 13, 2023 | Common Stock | 6.41K | $17.47 | Direct | F2 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -10K | -100% | 0 | Nov 13, 2023 | Common Stock | 10K | $12.75 | Direct | F3 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -10K | -100% | 0 | Nov 13, 2023 | Common Stock | 10K | $2.10 | Direct | F4 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -20K | -100% | 0 | Nov 13, 2023 | Common Stock | 20K | $3.00 | Direct | F5 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -40K | -100% | 0 | Nov 13, 2023 | Common Stock | 40K | $4.01 | Direct | F6 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -40K | -100% | 0 | Nov 13, 2023 | Common Stock | 40K | $3.31 | Direct | F7 | ||
transaction | SELB | Stock Option (Right to Buy) | Disposed to Issuer | -$69.8K | -75K | -100% | $0.93 | 0 | Nov 13, 2023 | Common Stock | 75K | $1.13 | Direct | F8 |
Id | Content |
---|---|
F1 | Held by TAS Partners LLC. The reporting person is the managing member of TAS Partners LLC. The reporting person disclaims beneficial ownership of the securities held by TAS Partners LLC except to the extent of his pecuniary interest therein, if any. |
F2 | This option, which provided for vesting in full on June 14, 2018, was canceled in the merger (the "Merger") between Selecta Biosciences, Inc. and Cartesian Therapeutics, Inc. |
F3 | This option, which provided for vesting in full on June 13, 2019, was canceled in the Merger. |
F4 | This option, which provided for vesting in full on June 14, 2020, was canceled in the Merger. |
F5 | This option, which provided for vesting in full on June 17, 2021, was canceled in the Merger. |
F6 | This option, which provided for vesting in full on March 30, 2022, was canceled in the Merger. |
F7 | This option, which provided for vesting in full on January 3, 2023, was canceled in the Merger. |
F8 | This option, which provided for vesting in full on January 2, 2024, was canceled in the Merger in exchange for a cash payment of $69,750, representing the difference between the exercise price of the option and $2.06, the Cash-out Amount as applied in the Merger. |